SR ONE CAPITAL MANAGEMENT, LP Q3 2025 Filing
Filed November 12, 2025
Portfolio Value
$691.4B
Holdings
12
Report Date
Q3 2025
Filing Type
13F-HR
All Holdings (12 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $192.7B | 27.86% | |
| 2 | CRSPCRISPR Therapeutics AG | 2,038,763 | $132.1B | 19.11% | |
| 3 | ZBIOZenas BioPharma, Inc | 4,911,539 | $109.0B | 15.77% | |
| 4 | MLYSMineralys Therapeutics Inc. | 2,113,933 | $80.2B | 11.59% | |
| 5 | ORICORIC Pharmaceuticals, Inc. | 4,514,929 | $54.2B | 7.84% | |
| 6 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $49.1B | 7.11% | |
| 7 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $40.3B | 5.83% | |
| 8 | ORKAOruka Therapeutics, Inc | 430,330 | $8.3B | 1.20% | |
| 9 | ALMSAlumis Inc. | 1,959,896 | $7.8B | 1.13% | |
| 10 | NKTXNkarta, Inc. | 3,333,333 | $6.9B | 1.00% | |
| 11 | OCSOculis Holding AG | 322,500 | $5.7B | 0.82% | |
| 12 | ENGNenGene Holdings Inc. | 747,750 | $5.1B | 0.74% |